CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner
Open accessAbstract
These findings suggest that combined treatment with CDK4/6i and anti-PD-1 antibody could improve the efficacy of anti-PD-1 therapy and hold great promise for the treatment of poorly immune-infiltrated ovarian cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CDK4/6 inhibitors improved the efficacy of α-PD-1 in murine models by enhancing lymphocyte infiltration and TIL activities.
“CDK4/6 inhibitors improved the efficacy of α-PD-1 in murine models by enhancing lymphocyte infiltration and TIL activities [245–248].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [245]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 51 · Cited by 177
Research works printed but not linked: 1
- [44]Rudensky AY Regulatory T cells and Foxp3 Immunol Rev 2011 241 260 8 21488902 PMC3077798
- Authors
- Zhang, Q.-F., Li, J., Jiang, K., Wang, R., Ge, J.-L., Yang, H., Liu, S.-J., Jia, L.-T., Wang, L., & Chen, B.-L.
- Affiliations
- Xijing Hospital (CN)
- Xi'an Honghui Hospital (CN)
- Xi'an Jiaotong University (CN)
- State Key Laboratory of Cancer Biology (CN)
- Corresponding author
- Wang, Lei
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 10
- Issue
- 23
- Pages
- 10619-10633
- ISSN
- 1838-7640 (ISSN-L)
- PMC
- PMC7482823
- OpenAlex
- W3082537053
- Cited by
- 177
- References
- 51
- Citations by year
- 2026: 14 · 2025: 44 · 2024: 56 · 2023: 28 · 2022: 26 · 2021: 9
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Theranostics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
- Keywords
- CDK4/6 inhibition, ovarian cancer, immune cell infiltration, anti-PD-1 therapy, B cells, combination therapy, tumor immunology
- MeSH terms
- Immune Checkpoint Inhibitors, Aminopyridines, Animals, Antineoplastic Combined Chemotherapy Protocols, B-Lymphocytes, Benzimidazoles, Disease Models, Animal, Drug Synergism, Female, Humans, Ovarian Neoplasms, CD4-Positive T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
